SEC Tracker
Get the app
ELTP · XBRL financial data

Elite Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ELTP's year ends in late March)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers141618*19191432*40363241*32
Cost of revenue8810*1011815*13221920*19
Gross profit678*88617*27141321*14
Research and development312*2222*2112*2
General and administrative222*2232*3428*4
Total operating expenses544*5556*66411*6
Operating income (loss)244*43111*228910*8
Interest income000*0000*0000*0
Interest expense000*0000*0000*0
Income tax expense (benefit)(18)(1)(1)*0202*5222*2
Net income (loss)1513*1(11)(11)17*(6)141918*6
Earnings per share, basic USD per share0.010.000.00*0.00(0.01)(0.01)0.02*(0.01)0.010.020.02*0.01
Earnings per share, diluted USD per share0.010.000.00*0.00(0.01)(0.01)0.02*(0.01)0.010.010.02*0.01
Weighted average shares, basic millions of shares1,0141,0151,019*1,0681,0681,0681,068*1,0681,0721,0741,077*1,077
Weighted average shares, diluted millions of shares1,0191,0241,035*1,0761,0681,0681,060*1,0681,1421,1411,203*1,129

Balance sheet

CSV

Fiscal quarters (ELTP's year ends in late March)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9679109122227223039
Accounts receivable101619202118293641496050
Inventory151413141420161918252124
Prepaid and other current assets011001110211
Total current assets35374043454858788697112114
Property and equipment, net101010111010101010101011
Right-of-use asset002222222221
Total assets71758488889196111117126138140
Accounts payable433326353766
Accrued liabilities111256644566106
Total current liabilities191913141315121111131730
Lease liability, non-current——2222211111
Total liabilities262826304154436456463935
Accumulated deficit(120)(120)(116)(116)(127)(138)(121)(127)(113)(94)(76)(70)
Total stockholders' equity4546585847365448628099105
Total liabilities and equity71758488889196111117126138140
Common shares outstanding (cover page) millions of shares1,0141,0181,0681,0681,0681,0681,0681,0711,0741,0771,0771,077

Cash flows

CSV

Fiscal quarters (ELTP's year ends in late March)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)1513*1(11)(11)17*(6)141918*6
Depreciation and amortization0*0*0*0000*0000*0
Net cash from operating activities(0)*(2)*2*31*(1)*4*155*(5)*9*10
Purchases of property and equipment——0*10*0*1*00*0*0*1
Net cash from investing activities——(0)*(2)0*0*(1)*(0)(0)*(0)*(0)*(1)
Net cash from financing activities(0)*(0)*(0)*(0)(0)*(0)*(0)*(4)(0)*(0)*(0)*(0)
Net change in cash(0)*(3)*1*11*(1)*3*105*(6)*9*9

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Elite Pharmaceuticals3932101.1B— 10-QJun 30, 2026
Iovance Biotherapeutics11199(61)*453.0M4.9 quarters 10-QJun 30, 2026
Opko Health301164(44)*746.3M6.9 quarters 10-Q/AJun 30, 2026
Savara42not reported(30)*205.5M5.8 quarters 10-QJun 30, 2026
Xencor4551(56)*74.4M6.8 quarters 10-QJun 30, 2026
Evolus4584(3.6)*66.1M12.6 quarters 10-QJun 30, 2026
KalVista Pharmaceuticals21441(14)53.2M19.7 quarters 10-QMar 31, 2026
Kura Oncology7021(63)*89.0M8.3 quarters 10-QJun 30, 2026
Myriad Genetics115191(8.3)*95.6M13.9 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.